Life sciences · 2026
SERINC2: From membrane lipid synthesis to human disease.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Son Changgyu, Lee Beomwoo, Choi Jaeseok, Bibi Ayesha, Ha Kyunghee, Ibrahim Sumaiya Othuman, Eom Sunho, Li Yuwen, Lee Jae Ho, Kim Seon-Hwan, Park Jongsun
Аннотация
AIMS: This review aims to summarize current evidence on the role of serine incorporator 2 (SERINC2) in human disease, focusing on how its function in serine-associated membrane lipid biosynthesis-particularly phosphatidylserine and sphingolipid metabolism-may contribute to disease-associated phenotypes across cancer, cardiovascular disease, and neuropsychiatric disorders.
MATERIALS AND METHODS: Relevant studies were identified through PubMed, Scopus, and Web of Science using search terms including "SERINC2," "serine incorporator," "phosphatidylserine," and "sphingolipid," alone and in combination with disease-related terms. Original research articles and relevant reviews published up to 2026 were included and prioritized according to the directness of their functional evidence for SERINC2.
KEY FINDINGS: In selected cancers, particularly lung adenocarcinoma and cervical cancer, SERINC2 has been associated with tumor cell proliferation, migration, and metabolic adaptation, whereas evidence in glioma remains largely association-based and thyroid cancer is supported by preliminary cell-line studies. In cardiovascular disease, SERINC2 has been implicated in pathological cardiac hypertrophy and septic cardiomyopathy through lysosome-associated nutrient sensing (amino acid/mTORC1) and Akt/GSK-3β-associated survival signaling, respectively. In neuropsychiatric disorders, genetic and expression-based evidence links SERINC2 to membrane-related neural processes, although direct mechanistic validation remains limited.
SIGNIFICANCE: Current evidence supports SERINC2 as an emerging, context-dependent disease-associated membrane protein whose membrane lipid regulatory functions may influence disease phenotypes. Clarifying tissue-specific mechanisms will determine whether SERINC2-associated pathways have clinical biomarker or therapeutic relevance.
MATERIALS AND METHODS: Relevant studies were identified through PubMed, Scopus, and Web of Science using search terms including "SERINC2," "serine incorporator," "phosphatidylserine," and "sphingolipid," alone and in combination with disease-related terms. Original research articles and relevant reviews published up to 2026 were included and prioritized according to the directness of their functional evidence for SERINC2.
KEY FINDINGS: In selected cancers, particularly lung adenocarcinoma and cervical cancer, SERINC2 has been associated with tumor cell proliferation, migration, and metabolic adaptation, whereas evidence in glioma remains largely association-based and thyroid cancer is supported by preliminary cell-line studies. In cardiovascular disease, SERINC2 has been implicated in pathological cardiac hypertrophy and septic cardiomyopathy through lysosome-associated nutrient sensing (amino acid/mTORC1) and Akt/GSK-3β-associated survival signaling, respectively. In neuropsychiatric disorders, genetic and expression-based evidence links SERINC2 to membrane-related neural processes, although direct mechanistic validation remains limited.
SIGNIFICANCE: Current evidence supports SERINC2 as an emerging, context-dependent disease-associated membrane protein whose membrane lipid regulatory functions may influence disease phenotypes. Clarifying tissue-specific mechanisms will determine whether SERINC2-associated pathways have clinical biomarker or therapeutic relevance.